Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666118 | 0.90 | SMN1; SMN2 (0.40) | EPHX2NR1H4MLYCDHDAC3HDAC1 | |
| SCHEMBL12800324 | 0.87 | POLB (0.42) | MLYCDLMNAKMT2AMEN1THRB | |
| SCHEMBL6947602 | 0.85 | PTGER4 (0.43) | MLYCDHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL4656671 | 0.84 | MLYCD (0.42) | EPHX2NR1H4MLYCDHDAC3HDAC1 | |
| SCHEMBL14804194 | 0.83 | KMT2A (0.48) | HDAC3HDAC1HDAC2NCOR2LMNA | |
| SCHEMBL6944145 | 0.81 | HCAR3 (0.47) | TSHRHTTALDH1A1POLB | |
| SCHEMBL6944148 | 0.81 | HCAR3 (0.47) | TSHRHTTALDH1A1POLB | |
| SCHEMBL27567687 | 0.80 | SMN1; SMN2 (0.39) | EPHX2NR1H4MLYCDHDAC3HDAC1 | |
| SCHEMBL13984783 | 0.78 | HDAC1 (0.49) | MLYCDHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6946720 | 0.76 | ALOX15 (0.39) | MLYCDHDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | EPHX2 4231/4885NR1H4 2825/4885MLYCD 2351/4885 |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | EPHX2 4231/4885NR1H4 2825/4885MLYCD 2351/4885 |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | EPHX2 4231/4885NR1H4 2825/4885MLYCD 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.